Pityriasis Lichenoides Chronica

What Is Pityriasis Lichenoides Chronica?

Pityriasis lichenoides chronica, often abbreviated PLC, is a chronic, generally benign inflammatory skin condition characterized by small, scaly, reddish brown bumps that develop gradually and tend to persist or recur over an extended period, often months to years.¹

PLC represents one end of a broader disease spectrum known as pityriasis lichenoides, with a more acute, sometimes more dramatic form called pityriasis lichenoides et varioliformis acuta, or PLEVA, representing the opposite end. Rather than being entirely separate conditions, PLC and PLEVA are now understood to reflect different expressions of the same underlying disease process.¹

The condition most commonly affects children and adolescents, with an average age of onset around six and a half years, though it can occur at any age and shows a modest predominance in males. Despite its persistent, sometimes frustrating course, PLC is generally considered a benign condition with a favorable long term outlook.²

PLEVA and PLC are not distinct diseases but are rather different manifestations of the same underlying process, representing the acute and chronic ends of the pityriasis lichenoides spectrum.
National Center for Biotechnology Information

Symptoms

PLC typically presents as small, reddish brown, scaly papules that appear gradually in crops, most commonly affecting the trunk, buttocks, and upper arms and legs, and individual lesions tend to flatten and fade slowly over the course of several weeks to months.²

Unlike its more acute counterpart PLEVA, PLC lesions generally cause little or no discomfort, and most patients experience minimal to no itching, which can make the condition easy to overlook or dismiss despite its persistent, visible nature.¹

Because new lesions tend to appear intermittently while older ones are still fading, PLC often produces a somewhat variable overall appearance at any given time, with spots at different stages of development or resolution visible simultaneously across affected areas of skin.²

Causes

The precise cause of PLC remains incompletely understood, and researchers have proposed several possible explanations, including an inflammatory reaction triggered by an underlying infection, and, less commonly considered, the possibility that the condition may represent a low grade disorder of T cell proliferation.¹

A meaningful body of research has specifically investigated a possible connection between PLC and streptococcal infection, with one randomized study finding a notable association between the two and demonstrating that targeted antibiotic treatment could produce meaningful clinical improvement in affected patients.³

Various other triggers have been reported in individual cases, including other infections, and, more recently, some reports describing PLC developing following vaccination, though these represent isolated observations rather than a clearly established causal pattern applicable to most patients.⁴

Risk Factors

Childhood and adolescence represent the periods of highest risk for developing PLC, with the condition most commonly diagnosed in school aged children, though adults can develop it as well, sometimes with a somewhat different clinical course.²

Male sex appears to be a modest risk factor, with several large case series finding a slight predominance of PLC among boys and male adolescents compared with their female counterparts.²

Age at disease onset appears to meaningfully influence prognosis, with research finding that patients whose disease begins after age five have a considerably higher likelihood of achieving remission compared with those whose disease begins at a younger age.⁵

Complications

PLC is generally considered a benign condition, and serious complications are uncommon, though the chronic, sometimes prolonged nature of the disease can be a source of ongoing frustration for patients and families, particularly when lesions persist for an extended period despite treatment.¹

In some patients, affected areas of skin can develop temporary changes in pigmentation, either lighter or darker than surrounding skin, once individual lesions resolve, though these changes typically fade gradually over time without specific treatment.²

While the vast majority of PLC cases follow a straightforward, benign course, ongoing medical monitoring remains reasonable given the historical, though now largely resolved, uncertainty regarding whether pityriasis lichenoides might occasionally represent an early lymphoproliferative process in rare cases.¹

Treatment

Many cases of PLC, particularly when mild and minimally symptomatic, are managed with observation alone, given the condition’s generally favorable natural course and tendency to eventually resolve without specific intervention.²

For patients with more extensive or persistent disease, oral antibiotics, particularly erythromycin or azithromycin, along with narrowband ultraviolet B phototherapy, represent commonly used first line treatment options when systemic therapy is warranted.³

Phototherapy has demonstrated strong effectiveness in clinical studies, with roughly eighty percent of treated patients achieving remission, and meaningful improvement often becoming apparent within the first several weeks of consistent treatment.⁶

Prevention

Because the precise cause of PLC remains incompletely understood, there is no clearly established or proven way to prevent the condition from developing.¹

Given the documented association between PLC and streptococcal infection in some patients, prompt evaluation and treatment of suspected streptococcal infections may play a role in managing or potentially reducing disease activity in affected individuals, based on available research.³

For patients already diagnosed with PLC, regular follow up with a dermatologist allows the overall pattern and course of the disease to be monitored over time, providing reassurance while confirming that the condition continues to follow its expected, generally benign trajectory.²

Why Visual Communication Matters for Pityriasis Lichenoides Chronica

Explaining how PLC relates to its more acute counterpart PLEVA, or why lesions at different stages of development can appear simultaneously across the skin, requires visuals that clearly illustrate this evolving, spectrum based skin condition to worried parents and patients.¹

Pharmaceutical companies, pediatric dermatology practices, and patient education organizations rely on clear illustration and animation to explain the biology behind PLC and to reassure families about its generally favorable long term course.

• Illustrating the relationship between PLC and PLEVA across the pityriasis lichenoides spectrum
• Animating how individual lesions progress from appearance to gradual resolution
• Explaining the proposed infectious and inflammatory mechanisms behind PLC
• Visualizing phototherapy treatment and its mechanism of action
• Supporting patient and caregiver education on expected disease course
• Creating training materials for pediatric dermatology clinicians

How Biotic Artlab Supports Pityriasis Lichenoides Chronica Communication

We work with pharmaceutical companies, pediatric dermatology practices, and patient education organizations to create accurate, engaging visuals that make PLC and its management easier to understand for families and clinicians alike.

• Custom 3D animations of skin lesion development and resolution in PLC
• Detailed illustrations comparing PLC with PLEVA across the disease spectrum
• Mechanism of action animations for phototherapy and antibiotic treatment
• Patient and caregiver facing educational materials on expected disease course
• Clinical training content for pediatric dermatology teams
• Conference presentations and marketing visuals for dermatology audiences

Frequently Asked Questions

Is pityriasis lichenoides chronica contagious?

No. PLC is an inflammatory skin condition, not a contagious infection, and it cannot be spread to other people through skin contact.¹

What is the difference between PLC and PLEVA?

They represent two ends of the same disease spectrum. PLEVA is the more acute, sometimes more dramatic form, while PLC represents a milder, more chronic, longer lasting presentation of the same underlying process.¹

Does PLC go away on its own?

Many cases eventually resolve, particularly when disease onset occurs after age five, though the condition can persist for months to years, and some patients benefit from treatment to help speed resolution and reduce visible lesions.⁵

Is PLC related to a bacterial infection?

Some research has found an association between PLC and streptococcal infection, and targeted antibiotic treatment has shown effectiveness in some studies, though not every case is linked to an identifiable infection.³

How effective is phototherapy for PLC?

Clinical studies have found that roughly eighty percent of patients treated with narrowband ultraviolet B phototherapy achieve remission, making it one of the more effective treatment options for more extensive or persistent disease.⁶

Does PLC leave permanent skin marks?

Temporary changes in skin pigmentation can occur after individual lesions resolve, but these changes typically fade over time and do not usually represent permanent scarring.²

Have a Project in Mind? Contact Us.

If you are developing patient education materials, clinical training content, or marketing visuals related to pityriasis lichenoides chronica or pediatric dermatology, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.

References

1. National Center for Biotechnology Information, StatPearls. Pityriasis Lichenoides Et Varioliformis Acuta.
2. National Center for Biotechnology Information. Clinical, Dermatoscopic, and Histological Findings in a Diagnosis of Pityriasis Lichenoides.
3. National Center for Biotechnology Information. Role of Streptococcal Infection in the Etiopathogenesis of Pityriasis Lichenoides Chronica and the Therapeutic Efficacy of Azithromycin, A Randomized Controlled Trial.
4. National Center for Biotechnology Information. Pityriasis Lichenoides Chronica Induced by COVID 19 Messenger RNA Vaccination.
5. National Center for Biotechnology Information. Pityriasis Lichenoides, Assessment of 41 Pediatric Patients.
6. National Center for Biotechnology Information. Pityriasis Lichenoides in Childhood, Review of Clinical Presentation and Treatment Options.

Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, emergency care, or individualized advice from a qualified healthcare professional.